LENZ Therapeutics Inc (LENZ)

Blue Owl Capital Holdings LP has acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ), purchasing 756,722 shares valued at approximately $4.30 million. This investment represents about 2.41% of LENZ Therapeutics and 0.6% of Blue Owl's portfolio. Despite LENZ shares trading near their one-year low, institutional ownership remains significant at 54.32%, and analysts hold a "Moderate Buy" consensus with an average price target of $28.80.

LENZ Therapeutics (NASDAQ:LENZ) reported its Q2 2026 earnings, detailing modest growth but significant increases in prescription starts during July following the launch of a telehealth platform and a national advertising campaign. The company highlighted strong patient persistence with over 60% of e-pharmacy patients repurchasing VIZZ, and an average annualized purchase rate of five monthly packs per patient. LENZ is expanding its global commercial footprint with five international partnerships and nine regulatory submissions under review, aiming for sustained patient growth and disciplined capital allocation.

Zacks Research has upgraded LENZ Therapeutics (NASDAQ:LENZ) from a "strong sell" to a "hold" rating, though other analysts remain divided, resulting in an overall "Moderate Buy" rating with an average price target of $28.80. The company's stock rose 2.8% to $4.73, while it reported better-than-expected quarterly results with a loss of $1.02 per share and revenue of $5.49 million, surpassing analyst estimates. Despite beating expectations, LENZ continues to post substantial losses, with analysts forecasting a full-year loss of $4.18 per share.

Analysts have cut LENZ Therapeutics, Inc.'s revenue estimates for 2026 and reduced their price target to US$26.83, despite lowering loss estimates. While the company beat revenue estimates in its latest report, future revenue is expected to decline significantly, underperforming the broader industry. This shift indicates increased pessimism regarding the company's intrinsic value.

Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism due to the revenue downgrade and expected underperformance compared to the broader industry. The wide range of analyst price targets suggests difficulty in accurately valuing the company's future.